Biotech companies continued to enjoy substantial investment in the first quarter, especially for early-stage companies. But the bulk of this capital was raised through initial public offerings (IPOs) in the US rather than Europe. Panelists at a recent BioTrinity conference in London debated whether this imbalance in funding opportunity was likely to have long-term term consequences for the European industry.
